IntelGenx Grants Stock Options


SAINT LAURENT, QUEBEC--(Marketwired - Aug. 31, 2017) - IntelGenx Technologies Corp. ("IntelGenx", or the "Company") (TSX VENTURE:IGX)(OTCQX:IGXT) announced today that the Company's board of directors granted options to acquire a total of 359,818 common shares under the 2016 Stock Option Plan.

Of the total stock options granted, 179,908 were granted to the Horst G. Zerbe, Chief Executive Officer and President and 59,970 were granted to Andre Godin, Executive Vice President and Chief Financial Officer. Furthermore, 59,970 stock options were granted to each of two officers of IntelGenx Corp., Nadine Paiement, Vice President Research and Development and Dana Matzen, Vice President of Business and Corporate Development.

The options have an exercise price of US$0.77 (CAD$0.96), vest over a period of two years at the rate of 25% every six months and expire on August 27, 2027.

About IntelGenx:

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx' highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx' state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTCQX accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

IntelGenx Technologies Corp.
Ingrid Zerbe
Corporate Secretary
514-331-7440
ingrid@intelgenx.com
www.intelgenx.com